Currently, the prostate cancer molecular imaging standardized evaluation criteria (PROMISE criteria) and the updated PROMISE V2 criteria have been proposed as a framework for whole-body staging to assess the prostate cancer disease extent on PSMA-PET. The gene discussed is FOLH1; the disease is prostate carcinoma.